Prognostic and predictive factors in primary breast cancer and their role in patient management: The Nottingham Breast Team

被引:81
作者
Rampaul, RS
Pinder, SE
Elston, CW
Ellis, IO
机构
[1] City Hosp Nottingham, Nottingham NHS Trust, Dept Histopathol, Nottingham NG1 5PB, England
[2] City Hosp Nottingham, Nottingham NHS Trust, Dept Surg, Nottingham NG1 5PB, England
来源
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY | 2001年 / 27卷 / 03期
关键词
breast cancer; prognostic factors; predictive factors;
D O I
10.1053/ejso.2001.1114
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Breast cancer is the most common carcinoma amongst women in the Western world, yet there are now encouraging signs that improvements in mortality may be a realistic target. Increasing breast awareness amongst women due to better health education can lead to earlier clinical detection. In addition, population screening with mammography can achieve a significant improvement in survival. With significant changes in the range and type of therapeutic options available for patients with breast cancer, there is now a trend towards patients exercising their right in management and therapeutic decisions, All these developments highlight the increasing importance of prognostic and predictive factors in the management of patients with breast cancer. In this review we will discuss current prognostic and predictive factors with particular emphasis on those of relevance in routine histopathology, especially with respect to their clinical applications, (C) 2001 Harcourt Publishers Ltd.
引用
收藏
页码:229 / 238
页数:10
相关论文
共 134 条
[1]   Lymphatic mapping and sentinel node biopsy in the patient with breast cancer [J].
Albertini, JJ ;
Lyman, GH ;
Cox, C ;
Yeatman, T ;
Balducci, L ;
Ku, NN ;
Shivers, S ;
Berman, C ;
Wells, K ;
Rapaport, D ;
Shons, A ;
Horton, J ;
Greenberg, H ;
Nicosia, S ;
Clark, R ;
Cantor, A ;
Reintgen, DS .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (22) :1818-1822
[2]  
ANDERSON TJ, 1999, IN PRESS HISTOPATHOL
[3]  
[Anonymous], BREAST
[4]   THE NOTTINGHAM-PROGNOSTIC-INDEX APPLIED TO 9,149 PATIENTS FROM THE STUDIES OF THE DANISH-BREAST-CANCER-COOPERATIVE-GROUP (DBCG) [J].
BALSLEV, I ;
AXELSSON, CK ;
ZEDELER, K ;
RASMUSSEN, BB ;
CARSTENSEN, B ;
MOURIDSEN, HT .
BREAST CANCER RESEARCH AND TREATMENT, 1994, 32 (03) :281-290
[5]   TIME TO ABANDON TNM STAGING OF BREAST-CANCER [J].
BARR, LC ;
BAUM, M .
LANCET, 1992, 339 (8798) :915-917
[6]   Phase II study of weekly intravenous recombinant humanized Anti-p185(HER2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast [J].
Baselga, J ;
Tripathy, D ;
Mendelsohn, J ;
Baughman, S ;
Benz, CC ;
Dantis, L ;
Sklarin, NT ;
Seidman, AD ;
Hudis, CA ;
Moore, J ;
Rosen, PP ;
Twaddell, T ;
Henderson, IC ;
Norton, L .
JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) :737-744
[7]  
BEAHRS OH, 1979, JNCI-J NATL CANCER I, V62, P641
[8]  
BEDWANI R, 1981, CANCER, V47, P2769, DOI 10.1002/1097-0142(19810615)47:12<2769::AID-CNCR2820471202>3.0.CO
[9]  
2-7
[10]  
BETTELHEIM R, 1984, BRIT J CANCER, V50, P771, DOI 10.1038/bjc.1984.255